Known allergy, hypersensitivity or contraindication to components of the FPA144 formulation including polysorbate or to platinum-containing medications, 5-FU, or leucovorin
Allergy or hypersensitivity to components of the KO-947 formulation, e.g. dextrose, hydroxypropyl beta cyclodextrin, acetic acid, sodium acetate and water for injection.
Known hypersensitivity to Apatinib or components of the formulation.
Known allergy or hypersensitivity to the components of the atezolizumab formulation.
The patient has a known allergy/history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab, or any other contraindication to one of the administered treatments
The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
A previously identified allergy or hypersensitivity to components of the study treatment formulation.
Allergy or hypersensitivity to components of the cobimetinib formulation
Has known allergy or reaction to any component of either study drug or formulation components
Allergy or hypersensitivity to components of the vemurafenib formulation
ENTRECTINIB EXCLUSION CRITERIA: Previously identified allergy or hypersensitivity to components of entrectinib formulation
A previously identified allergy or hypersensitivity to components of the study treatment formulation
The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
Previously identified allergy or hypersensitivity or intolerance to components of the study treatment formulation (cyclophosphamide, capecitabine, lapatinib [lapatinib ditosylate], trastuzumab)
Known allergy or hypersensitivity to the components of the atezolizumab formulation or to any of the study drugs or excipients, (e.g., Cremophor EL)
The subject has a previously-identified allergy or hypersensitivity to components of the study treatment formulation
Subject with known or suspected hypersensitivity to seviteronel, or any components of the formulation
Known allergy or hypersensitivity to components of the FPA144 formulation including polysorbate
For the Combination Dose Finding and Combination Expansion cohorts only: previously identified allergy or hypersensitivity to components of the study treatment formulation or panitumumab
Known hypersensitivity to any of plitidepsin's formulation components
Have a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab, or any other contraindication to one of the administered treatments.
The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
The participant has a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab or pembrolizumab, or any other contraindication to one of the administered treatments.
The patient has a previously-identified allergy or hypersensitivity to components of the study treatment formulation
The subject has a previously-identified allergy or hypersensitivity to components of the study treatment formulation
The participant has a previously identified allergy or hypersensitivity to components of the study treatment formulation
Subject has a known or suspected hypersensitivity to enzalutamide or any components of the formulation used.
Known allergy or hypersensitivity to any of the formulation components
The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
Subject has a previously-identified allergy or hypersensitivity to components of the study treatment formulation
Allergy or hypersensitivity to components of either study drug formulation
Allergy or hypersensitivity to components of the cobimetinib or GDC-0994 formulation
Known hypersensitivity to any involved study drug or any of its formulation components
The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
Allergy or hypersensitivity to components of the vemurafenib formulation
Allergy or hypersensitivity to components of the emactuzumab formulation or to components of the atezolizumab formulation
Allergy or hypersensitivity to components of the GDC-0994 formulation
